Testing KarXT for psychosis associated with Alzheimer's disease
Explore this study →
Everyone in this study is in one group and receives KarXT.
Sites in Calgary, Hamilton and 3 more cities
- Phase 3
- 1 group
- Sites in Calgary, Hamilton and 3 more cities
- Recruiting
Official title: Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Psychosis Associated With Alzheimer's Disease · Karuna Therapeutics, Inc., a Bristol Myers Squibb company